Retrophin (RTRX) Plans Presentations on Additional Phase 2 DUET Data as FSGS Treatment at ASN Event

October 21, 2016 11:10 AM EDT
Get Alerts RTRX Hot Sheet
Trade RTRX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Retrophin, Inc. (Nasdaq: RTRX) announced that additional data from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) will be presented at the late-breaking High-Impact Clinical Trials oral session at the American Society of Nephrology (ASN) Kidney Week 2016. Positive top-line results from the DUET study were announced in September 2016. The Company and its collaborators will also present further supportive data from the sparsentan program, as well as observational cohort data characterizing the association between proteinuria reduction and improved clinical outcomes in FSGS patients. ASN Kidney Week 2016 is being held November 15-20 in Chicago.

Oral Presentations

Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)Abstract #6478Session: High-Impact Clinical Trials Room W375C-ESaturday, November 19, 201612:10 p.m. CT

A Clinical Outcome Assessment of Proteinuria in Patients with Focal Segmental GlomerulosclerosisAbstract #1016Session: The Leaky Membrane: Nephrotic SyndromeRoom S106Friday, November 18, 20165:30 p.m. CT

Poster Presentations

Renal Pharmacology and Preclinical Attributes of Sparsentan, a Dually Active Endothelin A and Angiotensin 1 Receptor AntagonistAbstract #5728Session: Pathologic MechanismsPoster #TH-PO166Thursday, November 17, 201610:00 a.m. – 12:00 p.m. CT

Pharmacokinetics of Sparsentan in Healthy Subjects: In Vitro Metabolism and Effects of Food, Gender, Age, and Multiple-Dose EscalationAbstract #5751Session: Pharmaco: Kinetics, Dynamics, GenomicsPoster #SA-PO507Saturday, November 19, 201610:00 a.m. – 12:00 p.m. CT

Antihypertensive Effects of Sparsentan, a Dual Angiotensin II and Endothelin Type A Receptor AntagonistAbstract #5712Session: Hypertension: ClinicalPoster #SA-PO685Saturday, November 19, 201610:00 a.m. – 12:00 p.m. CT

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment